{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:27:22Z","timestamp":1750937242963},"reference-count":54,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3478,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1368-5031.2005.00830.x","type":"journal-article","created":{"date-parts":[[2006,2,22]],"date-time":"2006-02-22T12:50:30Z","timestamp":1140612630000},"page":"351-358","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of alfuzosin 10\u2003mg once daily in the treatment of symptomatic benign prostatic hyperplasia"],"prefix":"10.1155","volume":"60","author":[{"given":"L.","family":"Kuritzky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sadovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2006,2,22]]},"reference":[{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","article-title":"The development of human benign prostatic hyperplasia with age","volume":"132","author":"Berry","year":"1984","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB2|cit2","first-page":"1337","volume-title":"Campbell's Urology","author":"Lepor","year":"2002"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archinte.1995.00430050053006","article-title":"New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States","volume":"155","author":"Jacobsen","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB4|cit4","first-page":"S42","article-title":"A primary care physician's perspective on benign prostatic hyperplasia","volume":"5","author":"Kuritzky","year":"2003","journal-title":"Rev Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","article-title":"AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations","volume":"170","author":"AUA Practice Guidelines Committee.","year":"2003","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0022-5347(01)61785-3","article-title":"Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng\/ml or less","volume":"161","author":"Carvalhal","year":"1999","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-5347(05)67962-1","article-title":"Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study","volume":"163","author":"Roehrborn","year":"2000","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0090-4295(01)01155-4","article-title":"Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials","volume":"58","author":"Roehrborn","year":"2001","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.eururo.2003.08.015","article-title":"Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)","volume":"44","author":"Rosen","year":"2003","journal-title":"Eur Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.urology.2003.09.063","article-title":"Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function","volume":"63","author":"Kaplan","year":"2004","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000020246","article-title":"Medical therapy for benign prostatic hyperplasia: a review of the literature","volume":"38","author":"Clifford","year":"2000","journal-title":"Eur Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0090-4295(01)01322-X","article-title":"Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker","volume":"58","author":"Roehrborn","year":"2001","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB13|cit13","first-page":"169","article-title":"Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group","volume":"157","author":"Hansen","year":"1994","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1464-410X.1993.tb16298.x","article-title":"Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group","volume":"72","author":"Buzelin","year":"1993","journal-title":"Br J Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0024-3205(98)00257-4","article-title":"Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations","volume":"63","author":"Martin","year":"1998","journal-title":"Life Sci"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0302-2838(03)00154-4","article-title":"Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration","volume":"44","author":"Mottet","year":"2003","journal-title":"Eur Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000052316","article-title":"Preclinical pharmacology of alpha1-adrenoceptor antagonists","volume":"36","author":"Martin","year":"1999","journal-title":"Eur Urol"},{"issue":"Suppl. 2","key":"10.1111\/j.1368-5031.2005.00830.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000052230","article-title":"Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia","volume":"33","author":"Kirby","year":"1998","journal-title":"Eur Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000052361","article-title":"Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group","volume":"37","author":"Van Kerrebroeck","year":"2000","journal-title":"Eur Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0090-4295(01)01448-0","article-title":"Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial","volume":"58","author":"Roehrborn","year":"2001","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/j.1464-410X.2005.05456.x","article-title":"Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia","volume":"95","author":"Nordling","year":"2005","journal-title":"BJU Int"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1464-410X.2003.04309.x","article-title":"Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies","volume":"92","author":"Roehrborn","year":"2003","journal-title":"BJU Int"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0302-2838(01)00016-1","article-title":"Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study","volume":"41","author":"Van Kerrebroeck","year":"2002","journal-title":"Eur Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0090-4295(03)00657-5","article-title":"First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia","volume":"62","author":"Marks","year":"2003","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0090-4295(02)02371-3","article-title":"Benign prostatic hyperplasia: a progressive disease of aging men","volume":"61","author":"Emberton","year":"2003","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/0140-6736(91)93140-5","article-title":"Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group","volume":"337","author":"Jardin","year":"1991","journal-title":"Lancet"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.pcan.4500253","article-title":"Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice","volume":"1","author":"Lukacs","year":"1998","journal-title":"Prostate Cancer Prostate Dis"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1097\/01.ju.0000127743.80759.7a","article-title":"Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention","volume":"171","author":"McNeill","year":"2004","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.urology.2004.07.042","article-title":"Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study","volume":"65","author":"McNeill","year":"2005","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000473714","article-title":"Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy","volume":"29","author":"Lukacs","year":"1996","journal-title":"Eur Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000474449","article-title":"Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group","volume":"31","author":"Buzelin","year":"1997","journal-title":"Eur Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0090-4295(98)00126-5","article-title":"Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group","volume":"51","author":"Lepor","year":"1998","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1464-410X.2005.05347.x","article-title":"Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction","volume":"95","author":"Van Moorselaar","year":"2005","journal-title":"BJU Int"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.urology.2004.04.056","article-title":"Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation","volume":"64","author":"Rosen","year":"2004","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB37|cit37","unstructured":"UROXATRAL Sanofi-Synthelabo Inc. 2003"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB38|cit38","unstructured":"VIAGRA Pfizer Inc. 2003"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB39|cit39","unstructured":"CIALIS Lilly ICOS LLC 2005"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB40|cit40","unstructured":"LEVITRA Bayer HealthCare and GlaxoSmithKline 2005"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB41|cit41","first-page":"137","article-title":"Tadalafil shows no clinically significant haemodynamic interaction with the alpha-blocker alfuzosin 10 mg OD","volume":"4","author":"Giuliano","year":"2005","journal-title":"Eur Urol Suppl"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB42|cit42","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(18)35966-4","article-title":"Cardiovascular safety of the combination of vardenafil and alpha-blockers: a subgroup analysis of the postmarketing surveillance study Real Life Safety and Efficacy of Vardenafil (REALISE)","volume":"173","author":"Van Ahlen","year":"2005","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0090-4295(00)00744-5","article-title":"Alpha blockers: are all created equal?","volume":"56","author":"Debruyne","year":"2000","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2004.07.031","article-title":"State of the art on the efficacy and tolerability of alpha(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"64","author":"Djavan","year":"2004","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB45|cit45","unstructured":"CARDURA Pfizer Inc. 2001"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB46|cit46","unstructured":"FLOMAX Boehringer Ingelheim Pharmaceuticals, Inc. 2002"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB47|cit47","unstructured":"HYTRIN Abbott Laboratories 2001"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB48|cit48","unstructured":"AVODART GlaxoSmithKline 2003"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB49|cit49","unstructured":"PROSCAR Merck & Co., Inc. 2004"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0090-4295(01)01555-2","article-title":"Are all alpha-blockers created equal? An update","volume":"59","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0090-4295(00)01042-6","article-title":"Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia","volume":"57","author":"Narayan","year":"2001","journal-title":"Urology"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB52|cit52","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(18)35043-2","article-title":"Effects of alpha-blockers on ejaculatory function in normal subjects","volume":"173","author":"Hellstrom","year":"2005","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB53|cit53","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(18)35225-X","article-title":"Ejaculatory disorder induced by alpha-adrenergic receptor blockade is not retrograde ejaculation","volume":"173:","author":"Hisasue","year":"2005","journal-title":"J Urol"},{"key":"10.1111\/j.1368-5031.2005.00830.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000019996","article-title":"Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction","volume":"36","author":"Hofner","year":"1999","journal-title":"Eur Urol"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1368-5031.2005.00830.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1368-5031.2005.00830.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:06:13Z","timestamp":1643349973000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1368-5031.2005.00830.x"}},"subtitle":["ALFUZOSIN IN THE TREATMENT OF SYMPTOMATIC BPH"],"short-title":[],"issued":{"date-parts":[[2006,2,22]]},"references-count":54,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1111\/j.1368-5031.2005.00830.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2,22]]}}}